Revelation Partners
VC Fund
San Francisco, United States
Revelation Partners is a VC fund in San Francisco focused on Health Care and Biotechnology. Revelation Partners invests broadly across healthcare sectors with a focus on commercial companies with proven business models or companies with novel technologies that have clear clinical and regulatory pathways. They actively invest in the following healthcare verticals - medical devices, biopharmaceuticals, healthcare IT and healthcare services.
- Total investments:
- 57
- Last investment:
- Lead investor:
- 14%
- Fund size:
- $608M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Revelation Partners invests in
Stages Revelation Partners invests in
Countries Revelation Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Scott Halsted
|
|||
Eric Shiozaki
|
|||
Michael Boggs
|
|||
Rob Rein
|
Investment Focus
Industry
- Health Care 37 (65%)
- Biotechnology 19 (33%)
- Medical 17 (30%)
- Medical Device 11 (19%)
- Therapeutics 10 (18%)
Stage
- Series B 13 (23%)
- Series C 10 (18%)
- Series E 9 (16%)
- Funding Round 6 (11%)
- Series D 5 (9%)
Country
- United States 40 (70%)
- Brazil 1 (2%)
- Ireland 1 (2%)
- Switzerland 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Scott Halsted
Managing Partner
|
Managing Partner | Total investments: 10 | Find email | |
Doug Fisher
Partner and Liz Staley, Chief Compliance Officer
|
Partner and Liz Staley, Chief Compliance Officer | Total investments: 11 | Find email | |
|
Eric Shiozaki
Partner
|
Partner | Total investments: 4 | Find email | |
|
Michael Boggs
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
|
Rob Rein
Principal
|
Principal | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Quality Life Science Logistics & Transportation
|
Quality Life Science Logistics & Transportation specializes in cold chain transportation and freight services for pharmaceutical companies. | Private Equity / Dec 02, 2025 | |
Aspen Neuroscience
|
Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmetmedical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs. | $115M / Series C / Nov 20, 2025 | |
Arbor Biotechnologies
|
Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases. The company utilizes artificial intelligence and high-throughput screening to discover and optimize novel gene-editing systems. Its research focuses on expanding the CRISPR-based gene editing toolbox for therapeuticapplications. Arbor aims to develop treatments for rare and complex diseases by engineering precise and efficient genetic modifications. | $73.9M / Series C / Mar 18, 2025 | |
SPR Therapeutics
|
SPRA Therapeutics is a medical device company that is commercializing pain treatments utilizing its proprietary peripheral nerve stimulation (PNS) products. They are developing a pipeline of neurostimulation pain therapies that will exploit the same physiologic mechanism of action, proprietary technology, and clinical approach. The first product tobe commercialized is the SMARTPATCHâ„¢ PNS System, which is a short-term, minimally invasive system that is simple to deliver and can be used for up to 30 days to stimulate electrically a peripheral nerve to relieve pain. | $25M / Series D / Feb 01, 2024 | |
Nouscom
|
Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy.The NousCom team is lead by experiencedenterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies. | $73.4M / Series C / Nov 14, 2023 | |
Carrum Health
|
Healthcare is unreasonably complex and costly. At Carrum Health, they’re applying a common sense approach to simplify the payment model and produce greater value for employers and their employees. They do so by directly connecting progressive self-insured employers to top-quality regional healthcare providers through the industry’s firstcomprehensive bundled payment solution. Their innovative platform reimagines how care is paid for and delivered, improving the value of health benefits for employers and their members. | $45M / Series B / May 30, 2023 | |
Vedanta Biosciences
|
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $106.5M / Series E / Apr 25, 2023 | |
Bristol Hospice
|
Bristol Hospice programs are designed to promote quality and comprehensive services to our patients, families, and communities.It was formed in 2006, focusing on the delivery of hospice services in the geographic areas as identified in the company’s strategic plan. | Venture - Series Unknown / Jan 01, 2023 | |
Carrick Therapeutics
|
Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated. The company's therapeutics target molecular pathways that drive the most aggressive and resistant forms of cancer using innovative mechanisms, enabling cancer patients to get their predictive biomarkers detected and get their treatmentsstarted from early stage. | $60M / Series C / Dec 01, 2022 | |
Syapse
|
To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions thatmatter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond. | $35M / Venture - Series Unknown / Jul 27, 2022 | |
| See all 57 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Revelation Partners invest in?
Revelation Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 57 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Revelation Partners?
Public channels for Revelation Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Revelation Partners?
The team at Revelation Partners includes Scott Halsted (Managing Partner), Doug Fisher (Partner and Liz Staley, Chief Compliance Officer) and Eric Shiozaki (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
